<SEC-DOCUMENT>0001213900-24-033157.txt : 20240416
<SEC-HEADER>0001213900-24-033157.hdr.sgml : 20240416
<ACCEPTANCE-DATETIME>20240416080026
ACCESSION NUMBER:		0001213900-24-033157
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240416
FILED AS OF DATE:		20240416
DATE AS OF CHANGE:		20240416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		24846135

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0203923-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: April 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 16, 2024, Enlivex Therapeutics Ltd.,
a company organized under the laws of the State of Israel (&ldquo;Enlivex&rdquo;), issued a press release announcing that that the Danish
Medicines Agency authorized the expansion into Denmark of Enlivex&rsquo;s multi-country, randomized, controlled Phase I/II trial evaluating
Allocetra<SUP>TM</SUP> in up to 160 patients with moderate to severe knee osteoarthritis. A copy of such press release is furnished as
Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 90%"><A HREF="ea020392301ex99-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Press Release issued by Enlivex Therapeutics Ltd. on April 16, 2024.</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz </FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD STYLE="vertical-align: top">Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 16, 2024</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020392301ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON APRIL 16, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enlivex
Announces Authorization from the Danish Regulatory Agency for the Company&rsquo;s Randomized, Controlled Phase I/II Trial Evaluating
Allocetra in Patients with Knee Osteoarthritis </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) --</B> Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage
macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into
Denmark of the Company&rsquo;s multi-country, randomized, controlled Phase I/II trial evaluating Allocetra<SUP>TM</SUP> in up to 160
patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for
this trial from the Israeli Ministry of Health (IMOH) in January.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase I/II multi-center trial is composed of two stages. The first stage is a safety run-in, open-label dose escalation phase to characterize
the safety and tolerability of Allocetra&trade; injections to the target knee in order to identify the dose and injection regimen for
the second, randomized stage. The second stage is a double-blind, randomized, placebo-controlled stage, which the Company expects to
initiate following the completion of the safety run-in stage and confirmation by the independent Data and Safety Monitoring Board. In
addition to evaluating safety, the blinded randomized stage is statistically-powered to assess the efficacy of Allocetra&trade; injections
into the knee. The Company expects that the primary measurements will evaluate joint-pain and joint-function in comparison to placebo
at three months, six months and 12 months after treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
Hershkovitz, Ph.D., CEO of Enlivex, commented &ldquo;We are excited to push ahead with the clinical development of Allocetra<SUP>TM</SUP>
in osteoarthritis. The approval of the study in Denmark, which is expected to be the leading recruiting country in the trial, marks an
important step, as this is the first approval for this trial by a European agency. The Danish sites are experienced in conducting osteoarthritis
studies with high recruitment rates and high quality.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
KNEE OSTEOARTHRITIS<SUP>1</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Osteoarthritis
is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide.
About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis
by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing
knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States,
primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant
disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug
Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural
damage in the joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Source: The Arthritis Foundation; Disease modification in osteoarthritis; pathways to drug approval, Katz et. Al., Osteoarthritis
and Cartilage Open (2) (2020)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ALLOCETRA&trade;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocetra&trade;
is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases
such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages
contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra&trade; has the potential
to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as &quot;unmet medical
needs&quot;, as a stand-alone therapy or in combination with leading therapeutic agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ENLIVEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy
designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is
critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions. For more information, visit
http://www.enlivex.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safe
Harbor Statement:&nbsp; This press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;should,&rdquo; &ldquo;would&rdquo;, &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo;
&ldquo;has the potential to&rdquo; and other words of similar meaning, including statements regarding expected cash balances, market
opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities
for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and uncertainties
that may affect&nbsp;Enlivex&rsquo;s&nbsp;business and prospects, including the risks that&nbsp;Enlivex&nbsp;may not succeed in generating
any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or
effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied
or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties
that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage
trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product
line could also be affected by&nbsp;a number of&nbsp;other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.&nbsp; In addition
to the risk factors described above, investors should consider the economic, competitive, governmental,&nbsp;technological&nbsp;and other
factors discussed in&nbsp;Enlivex&rsquo;s&nbsp;filings with the Securities and Exchange Commission, including in the Company&rsquo;s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements contained
in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENLIVEX
CONTACT</B><BR>
Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR
RELATIONS CONTACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
Gentry, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip
Companies Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-407-644-4256</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENLV@redchip.com&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !^ ,D# 2(  A$! Q$!_\0
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M5_;,;8 XQJ(!.WPS@G;GQDB[LCY >L7A[]A+XB_%"YL_$G[1'Q5UK5;X*?\
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M,?\ @JU_P34\ $1^+/V^?V1]'N.\$GQ^^'%\P],+9>*&'\OZ@*5*L]H2_P#
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MLYX'.>V?;WI/LUM_SZ?J/\*OZPM=OZ^9T?ZJ5TM6]/\ +YG^P1XP_P""\?\
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M)6<JE63UE*=E>,$N6FG)\L5>]Y77T>0</O*6ZTKN4OBTN]=]7J]6]W]W6/\
M>?YVT?O/\[:/WG^=M'[S_.VOI3Z4/WG^=M'[S_.VC]Y_G;1^\_SMH /WG^=M
M'[S_ #MH_>?YVT?O/\[: #]Y_G;1^\_SMH_>?YVT?O/\[: #]Y_G;1^\_P [
M:/WG^=M'[S_.V@"T?];<_A57]Y_G;1^\_P [:/WG^=M !^\_SMH_>?YVT?O/
M\[:/WG^=M !^\_SMH_>?YVT?O/\ .VI))-D=RGKP.WMCOC].M -V3?9/\B/]
MY_G;1^\_SMK^J_\ ;#_9@_X((_L#>(?@A\)OC[\)O^"BOC'XF?$;]F_X0_'S
M7=8^%?Q2^$Q\';?B/HE[PI\3F+YS)H'B!V"JVU254LF'K\YOVA/&O_!!V\^#
MWQ%M_P!F'X-_\%%?#_QYN- ,7PKU?XO?$/X2:IX TWQ$"-I\0:3X8U$^+1IX
M7<"NP[B000 0Q]WI?\-CQ%G#;TC/KJE=:-KO>VG;JM-3\;LGU/YFC)]3^9K]
MI/%O_!,&ZN_^",'P#_X*=_"@>(M:O;3XI?%#P+^T_H-QJ!U33-"\)/X[;PQ\
M/O'N@B.Q7_A&+",V=GX1\=[I6#OXC\+$QX$JR>9?\$6_V0_A-^W=_P %&/@9
M^R[\<3XK/PS^(6@_%_5M>_X1+6!X8\3Y\-?"?Q+XF\/8UXHRE?\ A*?#UGF,
MJP8@@\/M"UTTWVU1T?VU2^JREHW%NZTNK=^J^[KZV_*/]Y_G;1^\_P [:_83
M_@E9^Q%\%?VP?CG^V-\//BW<>,SX9^!'[(7[1_QZ\"?\([KW]A:I_P )=\%K
MOP;'H!\0$JY_X1?;XC8CA26V_,N[<OX^VX\^.V_$#_( _P ].U/7T^?W_H5@
M\:L6VM%9)M;=[:6VTT[C?WG^=M'[S_.VOUW_ &/OV+?@W\:O^"8__!4G]K#Q
MM+XM_P"%M?L<C]G$?";^P]873?"O_%R?'C^&O$7_  D/A\H?^$C^10%W_=?Y
ME.YU%)^VG^QQ\(?AY_P3^_X)L?MO_ 2X\42Z=^TOX.^('PZ_: LO$NO_ /"1
M#0?VC_AIKAL_$3:!ML/^*;T7QEGQ"Z^$]V MB<A@Q*K?6R^=K_E^IQ_VQ;'-
M6T3<7K:UKK5Z6^_J?D3^\_SMH_>?YVU^KO\ P1O_ &*OA?\ MQ_M@7/@7X_R
M^)]+_9V^#_P6^+W[0/QVUCP;=#2M5TWP;\-]!P"-?(QX:'_"4Z_X>!R-I!P0
M<@CZJ_8!_98_X)N^,/V#?VT/V]/VTO!G[3_B3P'\$/VC_AO\+_!/@CX$>/M
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M*I_-E^VK_P $S/VW?^"?6G_#[5/VM_@HOPML?B??^(;'P3-%X^\!>,O[<O\
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M6W2[:6VNS_3?5/\ #+_@@#_R=[_P4T_[1J?MV_\ I_\ !U?S>6_^IMO^P?\
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M)Y?"EG\-?%WP^U[5_#%QH:ZHS^)/BROQ)T+6_#R^)A@>6V@A6R1G(('.*WO
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
